Etrasimod

Last Updated: 11/08/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 163 publications

S1P receptors in ulcerative colitis: spotlight on Etrasimod.

S1P receptors in ulcerative colitis: spotlight on Etrasimod.

Journal: Expert opinion on pharmacotherapy
Published: October 31, 2026

Etrasimod reduces circulating and mucosal inflammatory lymphocyte populations and alters innate immune and non-immune cell signatures in intestinal mucosa: ELEVATE UC phase 3 clinical data.

Etrasimod reduces circulating and mucosal inflammatory lymphocyte populations and alters innate immune and non-immune cell signatures in intestinal mucosa: ELEVATE UC phase 3 clinical data.

Journal: Journal of Crohn's & colitis
Published: October 13, 2026

The Efficacy and Safety of Etrasimod for the Induction and Maintenance of Remission in Moderate to Severe Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials.

The Efficacy and Safety of Etrasimod for the Induction and Maintenance of Remission in Moderate to Severe Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Journal: Cureus
Published: September 26, 2026

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Etrasimod (Velsipity® 2 mg tablets)

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Etrasimod (Velsipity® 2 mg tablets)

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: September 02, 2026

PANCCO Clinical Practice Guideline Update for the treatment of ulcerative colitis in adults

PANCCO Clinical Practice Guideline Update for the treatment of ulcerative colitis in adults

Journal: Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru
Published: July 25, 2026

Impact of Smoking on the Effectiveness of Advanced Therapies in Inflammatory Bowel Disease: Active Smoking Is Associated with Reduced Effectiveness of Anti-TNF Treatment.

Impact of Smoking on the Effectiveness of Advanced Therapies in Inflammatory Bowel Disease: Active Smoking Is Associated with Reduced Effectiveness of Anti-TNF Treatment.

Journal: Medicina (Kaunas, Lithuania)
Published: July 18, 2026

S1P receptor modulators for moderate-to-severe ulcerative colitis: a systematic review, meta-analysis, and trial sequential analysis.

S1P receptor modulators for moderate-to-severe ulcerative colitis: a systematic review, meta-analysis, and trial sequential analysis.

Journal: Journal of gastroenterology
Published: July 06, 2026

Beyond the Colon: Acute Hemolysis Associated With Etrasimod Therapy.

Beyond the Colon: Acute Hemolysis Associated With Etrasimod Therapy.

Journal: Cureus
Published: June 23, 2026

Ocular safety signals of sphingosine-1-phosphate receptor modulators in postmarketing surveillance.

Ocular safety signals of sphingosine-1-phosphate receptor modulators in postmarketing surveillance.

Journal: Frontiers in pharmacology
Published: June 14, 2026

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.

Journal: Paediatric drugs
Published: May 26, 2026

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Journal: Journal of Crohn's & colitis
Published: May 20, 2026

Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan.

Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan.

Journal: Advances in therapy
Published: May 18, 2026
Showing 1-12 of 163

Last Updated: 11/08/2026